Expertise in
15
conditions

Dr. Pasi A. Janne

Dana-Farber Cancer Institute, Inc.
Milford, MA
Expertise in
15
conditions
Specialties:Oncology
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
OverviewInsuranceLocationsClinical Research

Overview

Pasi Janne is an Oncologist in Milford, Massachusetts. Dr. Janne is highly rated in 15 conditions, according to our data. His top areas of expertise are EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Janne is currently accepting new patients.

His clinical research consists of co-authoring 378 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Tufts
  •  Cigna
  •  Aetna
  •  UnitedHealthcare
  •  Humana

Locations

DANA-FARBER CANCER INSTITUTE, INC.
20 Prospect St, Suite 2, Milford, MA 01757
508-473-1190
Other Locations
DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215
617-632-3000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 01, 2025
Intervention Type: Drug
Study Drugs: Osimertinib, Selumetinib
Study Phase: Phase 2
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutation
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2024
Intervention Type: Drug
Study Drug: DZD9008
Study Phase: Phase 1/Phase 2
A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2024
Intervention Type: Procedure, Drug, Biological
Study Drugs: Necitumumab, Osimertinib
Study Phase: Phase 1
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2024
Intervention Type: Drug
Study Drug: Osimertinib
Study Phase: Phase 2
A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Drug
Study Drugs: Gefitinib, Osimertinib
Study Phase: Phase 1/Phase 2
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Enapotamab vedotin 
Study Phase: Phase 1/Phase 2
MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies
MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies
Enrollment Status: Terminated
Publish Date: October 14, 2022
Intervention Type: Drug
Study Drug: BDTX-189
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors
Enrollment Status: Unknown
Publish Date: September 01, 2022
Intervention Type: Drug
Study Drug: RMC-4630
Study Phase: Phase 1
ALCMI-012 A Prospective Biospecimen Collection Study From Patients With EGFR Mutant Tumors
ALCMI-012 A Prospective Biospecimen Collection Study From Patients With EGFR Mutant Tumors
Enrollment Status: Withdrawn
Publish Date: January 09, 2020
A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers
A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers
Enrollment Status: Completed
Publish Date: August 07, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic NSCLC
Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic NSCLC
Enrollment Status: Completed
Publish Date: June 20, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

378 Total Publications

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 29, 2025
Similar Doctors
Robert J. Soiffer
Expertise in
26
conditions
Dr. Robert J. Soiffer
Oncology | Hematology
Expertise in
26
conditions
Dr. Robert J. Soiffer
Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

20 Prospect St, Suite 2, 
Milford, MA 
508-473-1190
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Soiffer is an Oncologist and a Hematologist in Milford, Massachusetts. Dr. Soiffer is highly rated in 26 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Hepatic Venoocclusive Disease with Immunodeficiency, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Graft. Dr. Soiffer is currently accepting new patients.

Expertise in
23
conditions
Dr. Toni K. Choueiri
Oncology
Expertise in
23
conditions
Dr. Toni K. Choueiri
Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (25.8 mi)
617-632-3000
Languages Spoken:
English, Arabic, French
Accepting New Patients
Offers Telehealth

Toni Choueiri is an Oncologist in Boston, Massachusetts. Dr. Choueiri is highly rated in 23 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Urothelial Cancer, Nephrectomy, and Orchiectomy. Dr. Choueiri is currently accepting new patients.

Expertise in
15
conditions
Dr. Michael S. Rabin
Oncology | Hematology
Expertise in
15
conditions
Dr. Michael S. Rabin
Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

20 Prospect St, Suite 2, 
Milford, MA 
508-473-1190
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Rabin is an Oncologist and a Hematologist in Milford, Massachusetts. Dr. Rabin is highly rated in 15 conditions, according to our data. His top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Rabin is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile